In a meta-analysis by Chu et al., the overall rate of RTX treating refractory AChR antibody-positive MG was 77% (p = 0.030) compared to the rate of RTX treating refractory MuSK antibody-positive MG to be 73% (p = 0.048) [12]. The gene discussed is MUSK; the disease is myasthenia gravis.